Acadia gets more rights for Daybue, forking over $100M upfront after an ‘impressive’ US launch

Acadia Pharmaceuticals is acquiring further rights to Neuren Pharmaceuticals’ newly approved Rett syndrome treatment for $100 million amid a better-than-expected launch of the drug.

The deal, announced Thursday, expands on a licensing agreement first set up in 2018 and deepens Acadia’s position in rare disease.

Click here to view original post